Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of “Hold” by Brokerages

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been given an average rating of “Hold” by the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $8.75.

A number of equities research analysts recently commented on CRDF shares. TD Cowen cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Craig Hallum lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Wednesday, June 3rd. Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Piper Sandler cut their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, HC Wainwright lowered shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st.

Cardiff Oncology Stock Up 2.0%

NASDAQ:CRDF opened at $1.53 on Wednesday. Cardiff Oncology has a 52 week low of $1.35 and a 52 week high of $4.56. The firm has a 50 day moving average of $1.66 and a 200 day moving average of $2.02. The stock has a market capitalization of $104.61 million, a price-to-earnings ratio of -2.28 and a beta of 1.36.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.09 million. As a group, analysts expect that Cardiff Oncology will post -0.66 EPS for the current year.

Institutional Trading of Cardiff Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group acquired a new stake in shares of Cardiff Oncology in the third quarter worth $26,000. Capital Advisors Wealth Management LLC acquired a new stake in shares of Cardiff Oncology in the fourth quarter worth $30,000. Tamar Securities LLC acquired a new stake in shares of Cardiff Oncology in the fourth quarter worth $32,000. R Squared Ltd acquired a new stake in shares of Cardiff Oncology in the fourth quarter worth $36,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Cardiff Oncology in the second quarter worth $43,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.